| ［1］ |
Sappey MPC. Anatomie， physiologie， pathologie de vaisseaux Lymphatiques［M］. Paris： Adrain Delahaye， 1874： 1-134
|
| ［2］ |
Suami H， Pan WR， Taylor GI. Historical review of breast lymphatic studies［J］. Clin Anat， 2009， 22（5）： 531-536.
|
| ［3］ |
Halsted WS. The results of radical operations for the cure of carcinoma of the breast［J］. Ann Surg， 1907， 46（1）：1-19.
|
| ［4］ |
Fisher B， Bauer M， Margolese R， et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer［J］. N Engl J Med， 1985， 312 （11）： 665-673.
|
| ［5］ |
Gould EA， Winship T， Philbin PH， et al. Observations on a “sentinel node” in cancer of the parotid ［J］. Cancer， 1960， 13： 77-78.
|
| ［6］ |
Cabanas RM. An approach for the treatment of penile carcinoma ［J］.Cancer， 1977， 39 （2）： 456-466.
|
| ［7］ |
Giuliano AE， Kirgan DM， Guenther JM， et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer ［J］. Ann Surg， 1994，220（3）： 391-398.
|
| ［8］ |
Krag DN， Weaver DL， Alex JC， et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe ［J］. Surg Oncol， 1993， 2 （6）： 335-339.
|
| ［9］ |
Krag DN， Anderson SJ， Julian TB， et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer： overall survival findings from the NSABP B-32 randomised phase 3 trial ［J］. Lancet Oncol， 2010， 11（10）： 927-933.
|
| ［10］ |
Mansel RE， Fallowfield L， Kissin M， et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer： the ALMANAC Trial ［J］. J Natl Cancer Inst，2006， 98（9）： 599-609.
|
| ［11］ |
Giuliano AE， Hawes D， Ballman KV， et al. Association of occult metastases in sentinel Lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer ［J］. JAMA，2011， 306（4）： 385-393.
|
| ［12］ |
Lyman GH， Somerfield MR， Bosserman LD， et al. Sentinel lymph node biopsy for patients with early-stage breast cancer： American Society of Clinical Oncology clinical practice guideline update ［J］. J Clin Oncol， 2017， 35（5）： 561-564.
|
| ［13］ |
王永胜， 欧阳涛， 王启堂， 等. 中国前哨淋巴结活组织检查多中心协作研究CBCSG-001最新资料报告［J/CD］. 中华乳腺病杂志（电子版）， 2009， 3（3）： 265-272.
|
| ［14］ |
Galimberti V， Cole BF， Viale G， et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases （IBCSG 23-01）： 10-year follow-up of a randomised，controlled phase 3 trial ［J］. Lancet Oncol， 2018， 19（10）： 1385-1393.
|
| ［15］ |
Sola M， Alberro JA， Fraile M， et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis： final results from the multicenter clinical trial AATRM 048/13/2000 ［J］. Ann Surg Oncol， 2013， 20（1）： 120-127.
|
| ［16］ |
Giuliano AE， Ballman KV， Mccall L， et al. Effect of axillary dissection vs no axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis： the ACOSOG Z0011 （Alliance） randomized clinical trial ［J］. JAMA，2017， 318（10）： 918-926.
|
| ［17］ |
Carlson RW， Allred DC， Anderson BO， et al. Invasive breast cancer［J］. J Natl Compr Canc Netw， 2011， 9（2）： 136-222.
|
| ［18］ |
Tinterri C， Gentile D， Gatzemeier W， et al. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes： the SINODAR-ONE multicenter randomized clinical trial ［J］. Ann Surg Oncol， 2022， 29（9）： 5732-5744.
|
| ［19］ |
Boniface JD， Tvedskov TF， Christiansen P， et al. Omitting axillary dissection in breast cancer with sentinel-node metastases［J］. N Engl J Med， 2024， 390（13）： 1163-1175.
|
| ［20］ |
Donker M， Van Tienhoven G， Straver ME， et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer（EORTC 10981-22023 AMAROS）： a randomised， multicentre， openlabel， phase 3 non-inferiority trial ［J］. Lancet Oncol， 2014， 15（12）：1303-1310.
|
| ［21］ |
Sávolt Á， Péley G， Mátrai Z， et al. Eight-year follow up result of the OTOASOR trial： the optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer： a randomized， single centre， phase III， non-inferiority trial ［J］. Eur J Surg Oncol， 2017， 43（4）： 672-679.
|
| ［22］ |
Goyal A， Mann GB， Miles E，et al. POSNOC-POsitive Sentinel NOde：adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy： a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes ［J］. BMJ Open， 2021， 11（12）：e054365.
|
| ［23］ |
Sun J， Mathias BJ， Lee MC， et al. Is it wise to omit sentinel node biopsy in elderly patients with breast cancer？ ［J］. Ann Surg Oncol，2021， 28（1）： 320-329.
|
| ［24］ |
Gentilini OD， Botteri E， Veronesi P， et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes： The SOUND randomized clinical trial ［J］. JAMA Oncol， 2023， 9（11）：1557-1564.
|
| ［25］ |
Reimer T， Stachs A， Gerber B， et al. Patient-reported outcomes for the Intergroup Sentinel Mamma study （INSEMA）： a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer ［J］. EClinicalMedicine， 2022， 55：101756.
|
| ［26］ |
Jung JG， Ahn SH， Lee S， et al. No axillary surgical treatment for lymph node-negative patients after ultra-sonography ［NAUTILUS］：protocol of a prospective randomized clinical trial ［J］. BMC Cancer，2022， 22（1）： 189.
|
| ［27］ |
Hersh EH， King TA. De-escalating axillary surgery in early-stage breast cancer ［J］. Breast， 2022， 62 Suppl 1： S43-S49.
|
| ［28］ |
Sun X， Wang XE， Zhang ZP， et al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients： results from the PEONY trial ［J］. Breast Cancer Res Treat， 2020， 180（2）：423-428.
|
| ［29］ |
Tadros AB， Yang WT， Krishnamurthy S， et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery ［J］.JAMA Surg， 2017， 152（7）： 665-670.
|
| ［30］ |
Geng C， Chen X， Pan X， et al. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy： A systematic review and metaanalysis ［J］. PLoS One， 2016， 11（9）： e0162605.
|
| ［31］ |
Kuehn T， Bauerfeind I， Fehm T， et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy（SENTINA）： a prospective， multicentre cohort study ［J］. Lancet Oncol， 2013， 14（7）： 609-618.
|
| ［32］ |
Gralow JR， Burstein HJ， Winer EP， et al. Preoperative therapy in invasive breast cancer： pathologic assessment and systemic therapy issues in operable disease ［J］. J Clin Oncol， 2008， 26（5）： 814-819.
|
| ［33］ |
Heidinger M， Weber WP. Axillary surgery for breast cancer in 2024［J］. Cancers （Basel）， 2024， 16（9）： 1623.
|
| ［34］ |
Boughey JC， Ballman KV， Le-petross HT， et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer （T0-T4， N1-N2） who receive neoadjuvant chemotherapy：Results from ACOSOG Z1071 （Alliance） ［J］. Ann Surg， 2016， 263（4）： 802-807.
|
| ［35］ |
Boileau JF， Poirier B， Basik M， et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer： the SN FNAC study ［J］. J Clin Oncol， 2015， 33（3）： 258-264.
|
| ［36］ |
Le-Petross HT， McCall LM， Boughey JC， et al. Axillary ultrasound identifies residual nodal disease after chemotherapy： results from the American college of surgeons oncology group Z1071 trial （Alliance）［J］. AJR Am J Roentgenol， 2018， 210（3）： 669-676.
|
| ［37］ |
Donker M， Straver ME， Wesseling J， et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients： the MARI procedure ［J］.Ann Surg， 2015， 261 （2）： 378-382.
|
| ［38］ |
Caudle AS， Yang WT， Krishnamurthy S， et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes：implementation of targeted axillary dissection ［J］. J Clin Oncol， 2016，34（10）： 1072-1078.
|
| ［39］ |
Zhang L， Cheng M， Lin Y， et al. Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer （ultraCars）：phase III randomized clinical trial ［J］. Br J Surg， 2022， 109（12）：1232-1238.
|
| ［40］ |
Van la Parra RF， Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders： historical perspective and current trials ［J］. Breast Cancer Res， 2016， 18（1）：28.
|
| ［41］ |
Montagna G， Mrdutt M， Botty A， et al. Oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemo-therapy： the OPBC-04/EUBREAST-06/OMA study ［DB/OL］.［2024-04-20］.https：//colab.ws/articles/10.1158/1538-7445.SABCS22-GS4-02.
|
| ［42］ |
Moo TA， Edelweiss M， Hajiyeva S， et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection［J］. Ann Surg Oncol， 2018， 25（6）： 1488-1494.
|
| ［43］ |
Montagna G. Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection？ The OPBC05/EUBREAST-14R/ICARO study ［DB/OL］.［2024-04-20］.https：//aacrjournals.org/cancerres/article/84/9_Supplement/GS02-02/743891/Abstract-GS02-02-Are-nodal-ITCs-after-neoadjuvant.
|
| ［44］ |
Davey MG， O'Flaherty C， Cleere EF， et al. Sentinel lymph node biopsy in patients with ductal carcinoma in situ： systematic review and meta-analysis ［J］. BJS Open， 2022， 6（2）：zrac022.
|
| ［45］ |
Si J， Guo R， Wu J， et al. Axillary evaluation is not warranted in patients preoperatively diagnosed with ductal carcinoma in situ by core needle biopsy ［J］. Cancer Med， 2019，8（18）：7586-7593.
|
| ［46］ |
Chiu CW， Chang LC， Su CM， et al. Precise application of sentinel lymph node biopsy in patients with ductal carcinoma in situ： A systematic review and meta-analysis of real-world data ［J］. Surg Oncol， 2022， 45： 101880.
|
| ［47］ |
Munck F， Clausen EW， Balslev E， et al. Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ ［J］. Br J Surg，2020， 107（1）： 96-102.
|
| ［48］ |
Karakatsanis A， Eriksson S， Pistiolis L， et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide（SPIO） nanoparticles： The SentiNot study ［J］. Ann Surg Oncol，2023， 30（7）： 4064-4072.
|
| ［49］ |
Veronesi U， Paganelli G， Viale G， et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer［J］. N Engl J Med， 2003， 349 （6）： 546-553.
|
| ［50］ |
Mamounas EP， Brown A， Anderson S， et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer： results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 ［J］. J Clin Oncol， 2005， 23 （12）： 2694-2702.
|
| ［51］ |
Classe JM， Loaec C， Gimbergues P， et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients： the GANEA 2 study ［J］.Breast Cancer Res Treat， 2019， 173 （2）： 343-352.
|
| ［52］ |
Henke G， Knauer M， Ribi K， et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer （TAXIS）： study protocol for a multicenter， randomized phase-III trial ［J］. Trials，2018， 19 （1）： 667.
|
| ［53］ |
Simons JM， van Nijnatten TJA， Smidt ML， et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer ［J］. JAMA Surg， 2022， 157（11）：991-999..
|
| ［54］ |
Kuemmel S， Heil J， Reinisch M， et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer ［J］. JAMA Surg， 2023， 158（8）： 807-815.
|
| ［55］ |
Wu SY， Li JW， Liu GY， et al. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy inbiopsy-proven node-positivebreastcancer：a prospective diagnostic and prognostic study ［J］. Int J Surg， 2023，109（7）： 1863-1870.
|